<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        210-368-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        YOCAIR 10MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Yocair&trade; is<br />Yocair&trade; is a leukotriene receptor antagonist that blocks substances called<br />leukotrienes.<br />How Yocair&trade; works<br />Leukotrienes cause narrowing and swelling of airways in the lungs and also cause<br />allergy symptoms. By blocking leukotrienes, Yocair&trade; improves asthma symptoms,<br />helps control asthma and improves seasonal allergy symptoms (also known as hay<br />fever or seasonal allergic rhinitis).<br />When Yocair&trade; should be used<br />Your doctor has prescribed Yocair&trade; to treat asthma, preventing your asthma<br />symptoms during the day and night.<br />&bull; Yocair&trade; is used for the treatment of adults and adolescents 15 years of age who are<br />not adequately controlled on their medication and need additional therapy.<br />&bull; Yocair&trade; also helps prevent the narrowing of airways triggered by exercise.<br />&bull; In those asthmatic patients in whom Yocair&trade; is indicated in asthma, Yocair&trade; can<br />also provide symptomatic relief of seasonal allergic rhinitis.<br />Your doctor will determine how Yocair&trade; should be used depending on the<br />symptoms and severity of your asthma.<br />What is asthma?<br />Asthma is a long-term disease. Asthma includes:<br />&bull; difficulty breathing because of narrowed airways. This narrowing of airways<br />worsens and improves in response to various conditions.<br />&bull; sensitive airways that react to many things, such as cigarette smoke, pollen, cold air,<br />or exercise.<br />&bull; swelling (inflammation) in the lining of airways.<br />Symptoms of asthma include: Coughing, wheezing, and chest tightness.<br />What are seasonal allergies?<br />Seasonal allergies (also known as hay fever or seasonal allergic rhinitis) are an<br />allergic response often caused by airborne pollens from trees, grasses and weeds.<br />The symptoms of seasonal allergies typically may include: stuffy, runny, itchy nose;<br />sneezing; watery, swollen, red, itchy eyes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies you have now or has had.<br />Do not take Yocair&trade;<br />&bull; if you are allergic to montelukast or any of the other ingredients of this medicine<br />(listed in section 6).<br />Take special care with Yocair&trade;<br />Talk to your doctor or pharmacist before taking Yocair&trade;.<br />&bull; If your asthma or breathing gets worse, tell your doctor immediately.<br />&bull; Oral Yocair&trade; is not meant to treat acute asthma attacks. If an attack occurs, follow<br />the instructions your doctor has given you. Always have your inhaled rescue<br />medicine for asthma attacks with you.<br />&bull; It is important that you take all asthma medications prescribed by your doctor.<br />Yocair&trade; should not be used instead of other asthma medications your doctor has<br />prescribed for you.<br />&bull; Any patient on anti-asthma medicines should be aware that if you develop a<br />combination of symptoms such as flu-like illness, pins and needles or numbness of<br />arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult<br />your doctor.<br />&bull; You should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines<br />(also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make your<br />asthma worse.<br />Patients should be aware that various neuropsychiatric events (for example behaviour<br />and mood-related changes) have been reported in adults, adolescents and children<br />with montelukast (see section 4). If you develop such symptoms while taking<br />montelukast , you should consult your doctor.<br />Children and adolescents<br />Do not give this medicine to children less than 15 years of age.<br />There are different form(s) of this medicine available for paediatric patients under<br />18 years of age based on age range.<br />Other medicines and Yocair&trade;<br />Tell your doctor or pharmacist if you are taking or has recently taken other<br />medicines, including those obtained without a prescription.<br />Some medicines may affect how Yocair&trade; works, or Yocair&trade; may affect how other<br />medicines work.<br />Tell your doctor if you are taking the following medicines before starting Yocair&trade;:<br />&bull; phenobarbital (used for treatment of epilepsy)<br />&bull; phenytoin (used for treatment of epilepsy)<br />&bull; rifampicin (used to treat tuberculosis and some other infections)<br />&bull; gemfibrozil (used for treatment of high lipid levels in plasma)<br />Yocair&trade; with food and drink<br />Yocair&trade; 10 mg film-coated tablet may be taken with or without food.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to<br />have a baby, ask your doctor or pharmacist for advice before taking Yocair&trade;.<br />Pregnancy<br />Your doctor will assess whether you can take Yocair&trade; during this time.<br />Breast-feeding<br />It is not known if Yocair&trade; appears in breast milk. You should consult your doctor<br />before taking Yocair&trade; if you are breast-feeding or intend to breast-feed.<br />Driving and using machines<br />Yocair&trade; is not expected to affect your ability to drive a car or operate machinery.<br />However, individual responses to medication may vary. Certain side effects (such as<br />dizziness and drowsiness) that have been reported very rarely with Yocair&trade; may<br />affect some patients&rsquo; ability to drive or operate machinery.<br />Important information about some of the ingredients of Yocair&trade;<br />Yocair&trade; 10 mg film-coated tablets contain lactose<br />If you have been told by your doctor that you have an intolerance to some sugars,<br />contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you.<br />Check with your doctor or pharmacist if you are not sure.<br />&bull; you should take only one tablet of Yocair&trade; once a day as prescribed by your<br />doctor.<br />&bull; It should be taken even when you have no symptoms or have an acute asthma<br />attack.<br />For adults and adolescents 15 years of age and older:<br />The recommended dose is one Yocair&trade; 10 mg tablet daily to be taken in the<br />evening.<br />If you are taking Yocair&trade;, be sure that you do not take any other products that<br />contain the same active ingredient, montelukast.<br />This medicine is for oral use.<br />You can take Yocair&trade; 10 mg with or without food.<br />If you take more Yocair&trade; than you should<br />Contact your doctor immediately for advice.<br />There were no side effects reported in the majority of overdose reports. The most<br />frequently occurring symptoms reported with overdose in adults and children<br />included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.<br />If you forget to take Yocair&trade;<br />Try to take Yocair&trade; as prescribed. However, if you miss a dose, just resume the<br />usual schedule of one tablet once daily.<br />Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Yocair&trade;<br />Yocair&trade; can treat your asthma only if you continue to take it.<br />It is important to continue taking Yocair&trade; for as long as your doctor prescribes. It<br />will help control your asthma.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets<br />them.<br />In clinical studies with montelukast 10 mg film-coated tablets, the most commonly<br />reported side effects (may affect up to 1 in 10 people) thought to be related to<br />montelukast were:<br />&bull; abdominal pain &bull; headache<br />These were usually mild and occurred at a greater frequency in patients treated with<br />montelukast than placebo (a pill containing no medication).<br />Serious side effects<br />Talk with your doctor immediately if you notice any of the following side effects,<br />which may be serious, and for which you may need urgent medical treatment.<br />Uncommon: the following may affect up to 1 in 100 people<br />&bull; allergic reactions including swelling of the face, lips, tongue, and/or throat which<br />may cause difficulty in breathing or swallowing<br />&bull; behaviour and mood related changes: agitation including aggressive behaviour or<br />hostility, depression<br />&bull; seizure<br />Rare: the following may affect up to 1 in 1,000 people<br />&bull; increased bleeding tendency &bull; tremor &bull; palpitations<br />Very rare: the following may affect up to 1 in 10,000 people<br />&bull; combination of symptoms such as flu-like illness, pins and needles or numbness of<br />arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss<br />syndrome) (see Section 2)<br />&bull; low blood platelet count<br />&bull; behaviour and mood related changes: hallucinations, disorientation, suicidal<br />thoughts and actions<br />&bull; swelling (inflammation) of the lungs<br />&bull; severe skin reactions (erythema multiforme) that may occur without warning<br />&bull; inflammation of the liver (hepatitis)<br />Other side effects while the medicine has been on the market<br />Very common: the following may affect more than 1 in 10 people<br />&bull; upper respiratory infection<br />Common: the following may affect up to 1 in 10 people<br />&bull; diarrhoea, nausea, vomiting<br />&bull; rash<br />&bull; fever<br />&bull; elevated liver enzymes<br />Uncommon: the following may affect up to 1 in 100 people<br />&bull; behaviour and mood related changes: dream abnormalities, including nightmares,<br />trouble sleeping, sleepwalking, irritability, feeling anxious, restlessness<br />&bull; dizziness, drowsiness, pins and needles/numbness<br />&bull; nosebleed<br />&bull; dry mouth, indigestion<br />&bull; bruising, itching, hives<br />&bull; joint or muscle pain, muscle cramps<br />&bull; bedwetting in children<br />&bull; weakness/tiredness, feeling unwell, swelling<br />Rare: the following may affect up to 1 in 1,000 people<br />&bull; behaviour and mood related changes: disturbance in attention, memory impairment,<br />uncontrolled muscle movements<br />Very rare: the following may affect up to 1 in 10,000 people<br />&bull; tender red lumps under the skin, most commonly on your shins (erythema nodosum)<br />&bull; behaviour and mood related changes: obsessive-compulsive symptoms, stuttering</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &ordm;C.<br />&bull; Do not use this medicine after the date shown following EXP on the blister and<br />carton.<br />&bull; Store in the original package in order to protect from light and moisture.<br />&bull; Medicines should not be disposed of via wastewater or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. These measures will help<br />to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is montelukast.<br />&bull; Yocair&trade; 10 mg film coated tablets each tablet contains 10.4 mg of Montelukast<br />Sodium equivalent to 10 mg Montelukast.<br />Core tablet content: Lactose Monohydrate, Croscarmellose sodium, Hydroxypropyl<br />cellulose, Microcrystalline cellulose, Magnesium stearate.<br />Coating content: Opadry yellow (which contains, Hypromellose, Hydroxypropyl<br />cellulose, titanium dioxide, carnauba wax, iron oxide yellow, iron oxide red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Yocair™ 10 mg film coated tablets are beige coloured, rounded square shaped, film
coated tablet, debossed with “JP” on one side and “98” on the other side
Yocair™ 10 mg film coated tablets are available in packs of 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111,<br />Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />Please report adverse drug events to:<br />The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما ھو یوكیر<br />من مناھضات مُستقبِلات اللیكوترین التي تقوم بحصر نشاط مواد تُسمى اللیكوترینات. &trade; یُعد یوكیر<br />&trade; كیفیة عمل یوكیر<br />تؤدي اللیكوترینات إلى انقباض وتورم الممرات الھوائیة في الرئتین وتسبب أیضًا أعراض الحساسیة. عن<br />أعراض مرض الربو ویساعد على السیطرة على حالة &trade; طریق حصر نشاط اللیكوترینات یُحسن یوكیر<br />الربو ویحسن أعراض الحساسیة الموسمیة (المعروف أیضا باسم حمى القش أو التھاب الأنف التحسسي<br />الموسمي).<br />&trade; متى یجب استعمال یوكیر<br />لعلاج حالة الربو لدیك والوقایة من أعراض الربو أثناء النھار واللیل. &trade; لقد وصف لك طبیبك یوكیر<br />للمرضى من البالغین والمراھقین من عمر ۱٥ عام ممن لا یسیطر علاجھم الحالي على &trade; &bull; یُستخدم یوكیر<br />مرضھم بشكل كاف ویحتاجون لعلاج إضافي.<br />أیضًا على الوقایة من انقباض الممرات الھوائیة الناجم عن بذل مجھود. &trade; &bull; یُساعد یوكیر<br />أیضا تخفیف &trade; في الربو ، یمكن أن یوفر یوكیر &trade; &bull; مع المرضى الذین یعانون من الربو ووصف لھم یوكیر<br />لأعراض التھاب الأنف التحسسي الموسمي.<br />وفقا لأعراض وشدة الربو لدیك. &trade; سیقرر الطبیب كیفیة استخدام یوكیر<br />ما ھو الربو؟<br />الربو ھو مرض طویل الأمد. تتضمن أعراض الربو:<br />&bull; صعوبة في التنفس بسبب انقباض الممرات الھوائیة. تتحسن أو تتفاقم حالة انقباض الممرات الھوائیة<br />استجابة لظروف مختلفة.<br />&bull; لدى الممرات الھوائیة حساسیة تجاه عدة أشیاء، مثل: دخان السجائر وحبوب اللقاح والھواء البارد أو بذل<br />مجھود شدید.<br />&bull; تورم (التھاب) في بطانة مجرى الممرات الھوائیة.<br />تتضمن أعراض الربو: سعال وصفیر عند التنفس أو الزفیر وضیق في الصدر.<br />ما ھي الحساسیة الموسمیة؟<br />الحساسیة الموسمیة (تعرف أیضا باسم حمى القش أو التھاب الأنف التحسسي الموسمي) ھي استجابة<br />تحسسیة غالبا ما تسببھا حبوب اللقاح المحمولة جوا من الأشجار والأعشاب والحشائش. أعراض الحساسیة<br />الموسمیة قد تشمل عادة: انسداد، سیلان، حكة في الأنف; عطس; تدمع ، إنتفاخ ، إحمرار ، حكة في<br />العینین.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یجب أن تخبر طبیبك بأیة مشاكل صحیة أو حساسیة تعاني أو كنت تعاني منھا سابقا.<br />في الحالات الآتیة: &trade; یمنع تناول یوكیر<br />&bull; إذا كنت تُعاني من حساسیة مفرطة تجاه مونتیلوكاست أو أي مكون من المكونات الأخرى الداخلة في<br />.( تركیب ھذا الدواء (المُدرجة في قسم ٦<br />&trade; الاحتیاطات الواجب اتخاذھا عند تناول یوكیر<br />.&trade; استشر طبیبك أو الصیدلي قبل أن تتناول یوكیر<br />&bull; یرجى أن تخبر طبیبك على الفور إذا حدث تدھور في حالة الربو لدیك أو ساءت عملیة التنفس لدیك.<br />عن طریق الفم للإغاثةِ الفوریةِ مِنْ نوبات الربو الحادة. عند حدوث نوبة ربو، یجب &trade; &bull; لا یستخدم یوكیر<br />علیك اتباع التعلیمات التي أعطاھا طبیبك لك. احرص دائمًا على أن تصطحب معك دواء الاستنشاق<br />الإنقاذي الخاص بعلاج نوبات الربو.<br />&bull; من المھم أن تتناول جمیع أدویة الربو التي وصفھا طبیبك.<br />كبدیل عن أدویة الربو الأخرى التي وصفھا طبیبك لك . &trade; یُحظر استخدام یوكیر<br />&bull; یجب أن یُدرك أي مریض یُعالج بأدویة مضادة للربو أنھ یجب علیھ استشارة الطبیب إذا عانى من<br />أعراض مشابھة للإنفلونزا، و/أو وخز &quot;الإبر أو المسامیر&quot; أو التَّنمیل في الذراعین أو الساقین، و/أو<br />تدھور الأعراض الرئویة، و/أو الطفح الجلدي.<br />&bull; یجب ألا تتناول حمض أسیتیل سالیسیلیك (الأسبرین) أو أي أدویة مضادة للالتھاب (تعرف أیضًا باسم<br />مضادات الالتھاب غیر الستیرویدیة) إذا كانت تؤدي إلى تدھور حالة الربو لدیك.<br />یجب أن یكون المرضى على درایة بأنھ تم الإبلاغ عن العدید من الأحداث النفسیة العصبیة (على سبیل<br />المثال التغیرات المرتبطة بالسلوك و المزاج) لدى البالغین والمراھقین والأطفال مع مونتیلوكاست (انظر<br />القسم ٤). إذا ظھرت علیك ھذه الأعراض أسثناء تناول مونتیلوكاست ، یجب علیك استشارة طبیبك.<br />الأطفال والمراھقون<br />تجنب إعطاء ھذا الدواء للأطفال دون ۱٥ عام.<br />ھناك شكل مختلف/أشكال مختلفة من ھذا الدواء متوفرة للمرضى من الأطفال دون ۱۸ عامًا بناء على الفئة<br />العمریة.<br />&trade; تناول الأدویة الأخرى مع یوكیر<br />یُرجى إبلاغ الطبیب أو الصیدلي الخاص بك إذا كنت تتناول أو قد تناول أي أیة أدویة أخرى مؤخرًا بما في<br />ذلك الأدویة التي تم الحصول علیھا بدون وصفة طبیة.<br />على آلیة عمل أدویة أخرى &trade; أو قد یؤثر یوكیر ،&trade; قد تؤثر بعض الأدویة على آلیة عمل یوكیر<br />:&trade; أخبر طبیبك إذا كنت تتناول الأدویة التَّالیة قبل البدء في تناول یوكیر<br />&bull; فینوباربیتال (یستخدم لعلاج الصرع)<br />&bull; فینیتوین (یستخدم لعلاج الصرع)<br />&bull; ریفامبیسین (یستخدم لعلاج السل وبعض أنواع الأمراض المعدیة الأخرى)<br />&bull; جیمفیبروزیل (یستخدم لعلاج ارتفاع مستویات الدھون في البلازما)<br />مع الطعام والمشروبات &trade; تناول یوكیر<br />۱۰ ملجم أقراص مغلفة مع الطعام أو بدونھ. &trade; یمكن تناول یوكیر<br />الحمل والرضاعة الطبیعیة<br />إذا كنتِ حاملًا أو تمارسین الإرضاع الطبیعي أو تعتقدین أنكِ حامل أو تخططین لذلك، فاستشیري طبیبك<br />.&trade; أو الصیدلي قبل تناوُل یوكیر<br />الحمل<br />خلال ھذا الوقت أم لا. &trade; سیقرر طبیبك إذا كان بإمكانك تناول یوكیر<br />الرضاعة الطبیعیة<br />إذا &trade; یمر إلى لبن الأم. یجب علیكِ استشارة طبیبك قبل تناول یوكیر &trade; من غیر المعروف ما إذا كان یوكیر<br />كنتِ مرضعةً أو تنوین ممارسة الإرضاع الطبیعي.<br />القیادة واستخدام الآلات<br />على قدرتك على قیادة سیارة أو تشغیل الآلات. ومع ذلك، قد تختلف &trade; من غیر المتوقع أن یؤثر یوكیر<br />ا ما تظھر 􀌒 استجابة كل فرد عن الآخر تجاه الدواء. تم الإبلاغ عن بعض الأعراض الجانبیة التي نادرًا جد<br />مثل الدوخة والخمول) والتي قد تؤثر على قدرة بعض المرضى على القیادة أو ) &trade; عند استخدام یوكیر<br />تشغیل الآلات.<br />&trade; معلومات مھمة عن بعض مكونات یوكیر<br />۱۰ ملجم المغلفة على اللاكتوز &trade; تحتوي أقراص یوكیر<br />إذا أخبرك طبیبك بأن لدیك حساسیة تجاه بعض السكریات ، استشر طبیبك قبل أخذ ھذا المنتج الطبي.</p><p>في حالة توقفك عن تناول یوكیر<br />حالة الربو لدیك إذا إستمریت في تناولھ. &trade; یمكن أن یعالج یوكیر<br />طوال المدة التي وصفھا لك الطبیب. سیساعد ذلك في السیطرة على &trade; من المھم أن تستمر في تناول یوكیر<br />حالة الربو التي تعاني منھا.<br />إذا كانت لدیك أیة أسئلة أخرى متعلقة باستخدام ھذا الدواء، فاستشر الطبیب المعالج لك أو الصیدلي الخاص<br />بك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا ھذا الدَّواء كما أخبرك طبیبك أو الصیدلي الخاص بك بالضبط. یُرجى مراجعة طبیبك أو<br />الصیدلي إذا لم تكن متأكدًا من كیفیة الاستخدام.<br />ا على النحو الذي وصفھ طبیبك. 􀌒 مرة واحدة یومی &trade; &bull; یجب أن تتناول قرصًا واحدًا فقط من یوكیر<br />&bull; یجب أن یتم تناول الدواء حتى إذا لم تكن تعاني من أي أعراض أو إذا كنت تعاني من نوبة ربو حادة.<br />للبالغین والمراھقین في سن ۱٥ سنة وما فوق:<br />۱۰ ملجم أقراص مغلفة. &trade; الجرعة الموصى بھا ھي قرص واحد یومیًا في المساء من یوكیر<br />فتأكد من عدم تناول أیة أدویة أخرى تحتوي على نفس المادة الفعالة، ،&trade; إذا كنت تتناول یوكیر<br />مونتیلوكاست.<br />ھذا الدواء مخصص للتناوُل عن طریق الفم.<br />۱۰ ملجم أقراص مغلفة مع الطعام أو بدونھ. &trade; یمكن تناول یوكیر<br />فیجب علیك ،&trade; في حالة تناولك كمیة أكثر من اللازم من یوكیر<br />الاتصال بطبیبك فورًا للحصول على مشورة طبیة.<br />لم یتم رصد أي آثار جانبیة في غالبیة تقاریر الجرعة الزائدة. تضمنت الأعراض التي تم رصدھا بشكل<br />أكثر تكرارًا عند تناول البالغین والأطفال جرعة زائدة: ألم في البطن ونعاس وعطش وصداع وقيء وفرط<br />النشاط.<br />&trade; إذا نسیت تناول یوكیر<br />وفقًا لما تم وصفھ لك. ومع ذلك، إذا فاتتك جرعة، فاستأنف جدول مواعید الجرعات &trade; حاول تناول یوكیر<br />ا. 􀌒 المعتاد المكون من قرص واحد مرة واحدة یومی<br />لا تتناول جرعة مضاعفة لتعویض الجرعة الفائتة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثلھ مثل كافة الأدویة، قد یُسبب ھذا الدواء آثارًا جانبیة، على الرغم من عدم حدوثھا لدى الجمیع.<br />في الدراسات السریریة التي أجریت باستخدام مونتیلوكاست ۱۰ ملجم أقراص مغلفة، كانت الآثار الجانبیة<br />الأكثر شیوعًا التي تم الإبلاغ نتیجة تناول الأطفال لمونتیلوكاست (قد تؤثر على شخص واحد من كل ۱۰<br />أشخاص) ھي:<br />&bull; ألم في البطن &bull; صداع<br />عادة ما كانت ھذه الآثار الجانبیة طفیفة وتحدث بمعدل أكبر لدى المرضى الذین تم علاجھم بمونتیلوكاست<br />مقارنة بالمرضى الذین تم علاجھم بالعقار الوھمي (حبة لا تحتوي على دواء).<br />آثار جانبیة خطیرة<br />تحدث مع طبیبك على الفور إذا لاحظت أیًا من الآثار الجانبیة التالیة ، والتي قد تكون خطیرة ، والتي قد<br />تحتاج إلى علاج طبي عاجل.<br />غیر شائعة: قد تؤثر على ما یصل إلى شخص من بین كل ۱۰۰ شخص<br />&bull; تفاعلات الحساسیة، وتشمل: تورم الوجھ و/أو والشفاه و/أو واللسان و/أو الحلق الذي قد یؤدي إلى<br />صعوبة في التنفس أو البلع<br />&bull; تغییرات مرتبطة بالسلوك والحالة المزاجیة: الانفعال بما في ذلك السلوك العدواني أو العداء والاكتئاب<br />&bull; تشنجات<br />نادرة: قد تؤثر على ما یصل إلى شخص من بین كل ۱,۰۰۰ شخص<br />&bull; زیادة القابلیة للنزف<br />&bull; رعشة<br />&bull; خفقان<br />ا: قد تُؤثر على ما یصل إلى شخص من بین كل ۱۰,۰۰۰ شخص 􀌒 نادرة جد<br />&bull; مجموعة من الأعراض تشبھ مرض الأنفلونزا ، وخز &quot;الإبر أو المسامیر&quot;/تنمیل الذراعین والساقین ،<br />( تفاقم الأعراض الرئویة و / أو الطفح الجلدي (متلازمة تشورج شتراوس) (انظر القسم ۲<br />&bull; انخفاض عدد الصفائح الدمویة<br />&bull; تغییرات مرتبطة بالسلوك والحالة المزاجیة: ھلوسات، توھان، التفكیر في الانتحار وأفعال انتحاریة<br />&bull; تورم (التھاب) في الرئتین<br />&bull; تفاعلات جلدیة شدیدة (حمامي عدیدة الأشكال) قد تحدث دون سابق إنذار<br />&bull; التھاب الكبد<br />بالإضافة إلى ذلك، فقد تم رصد الآثار الجانبیة التالیة بعد طرح الدَّواء في الأسواق:<br />ا: قد تُؤثر على أكثر من شخص من بین كل ۱۰ أشخاص 􀌒 شائعة جد<br />&bull; عدوى الجھاز التَّنفسي العلوي<br />شائعة: قد تؤثر على ما یصل إلى شخص من بین كل ۱۰ أشخاص<br />&bull; الإسھال والغثیان والقيء<br />&bull; طفح جلدي<br />&bull; حمة<br />&bull; ارتفاع انزیمات الكبد<br />غیر شائعة: قد تؤثر على ما یصل إلى شخص من بین كل ۱۰۰ شخص<br />&bull; التغیرات المرتبطة بالسلوك والمزاج: تشوھات الأحلام ، بما في ذلك الكوابیس ، مشاكل النوم ، السیر<br />أثناء النوم ، التھیج ، الشعور بالقلق ، والأرق.<br />&bull; دوار ، نعاس ، دبابیس وإبر / تنمیل<br />&bull; نزیف الأنف<br />&bull; جفاف الفم ، عسر الھضم<br />&bull; كدمات ، حكة ، خلایا<br />&bull; ألم في المفاصل أو العضلات ، وتشنجات العضلات<br />&bull; التبول اللاإرادي عند الأطفال<br />&bull; الضعف / التعب ، والشعور بتوعك ، وتورم<br />نادرة: قد تؤثر على ما یصل إلى شخص من بین كل ۱,۰۰۰ شخص<br />&bull; التغیرات المرتبطة بالسلوك والمزاج: اضطراب في الانتباه ، ضعف الذاكرة ، حركات العضلات غیر<br />المنضبط<br />ا: قد تُؤثر على ما یصل إلى شخص من بین كل ۱۰,۰۰۰ شخص 􀌒 نادرة جد<br />&bull; تكون كتل حمراء مؤلمة تحت الجلد تحدث بشكل شائع في السیقان (احمرار عقدي)<br />&bull; التغیرات المتعلقة بالسلوك والمزاج ، أعراض الوسواس القھري ، التأتأة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; یحفظ بعیداً عن متناول و مرأى الأطفال .<br />&bull; یحفظ في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />.EXP بعد تاریخ انتھاء الصلاحیة المدون على الشرائط و على العبوة بعد &trade; &bull; لا تستخدم یوكیر<br />&bull; یحفظ في العلبة الأصلیة للحمایة من الضوء و الرطوبة.<br />&bull; لا ینبغي التخلص من الأدویة عبر بالوعات الصرف أو ضمن مخلفات المنزل. اسأل الصیدلي الخاص بك<br />عن طریقة التخلص من الأدویة التي لم تعد بحاجة إلیھا. ستساعد ھذه التدابیر في حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا یحتوي یوكیر<br />المادة الفعالة ھي: مونتیلوكاست.<br />۱۰ ملجم أقراص مغلفة على ۱۰,٤ ملجم من مونتیلوكاست الصودیوم مما &trade; &bull; یحتوي كل قرص من یوكیر<br />یكافئ ۱۰ ملجم مونتیلوكاست.<br />&bull; المكونات الأخرى ھي: محتوي لب القرص : لاكتوز مونوھیدرات، كروس كارمیلوز الصودیوم،<br />ھیدروكسي بروبیل السلیلوز، سلیلوز دقیق التبلور، ستیرات الماغنسیوم.<br />محتوى غلاف القرص : أوبادري أصفر (الذي یحتوي على ، ھیبرومیلوز، ھیدروكسي بروبیل السلیلوز ،<br />ثاني أكسید التیتانیوم ، شمع كرنوبا ، أكسید الحدید الأصفر ، أكسید الحدید الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">على ماذا یحتوي یوكیر<br />المادة الفعالة ھي: مونتیلوكاست.<br />۱۰ ملجم أقراص مغلفة على ۱۰,٤ ملجم من مونتیلوكاست الصودیوم مما &trade; &bull; یحتوي كل قرص من یوكیر<br />یكافئ ۱۰ ملجم مونتیلوكاست.<br />&bull; المكونات الأخرى ھي: محتوي لب القرص : لاكتوز مونوھیدرات، كروس كارمیلوز الصودیوم،<br />ھیدروكسي بروبیل السلیلوز، سلیلوز دقیق التبلور، ستیرات الماغنسیوم.<br />محتوى غلاف القرص : أوبادري أصفر (الذي یحتوي على ، ھیبرومیلوز، ھیدروكسي بروبیل السلیلوز ،<br />ثاني أكسید التیتانیوم ، شمع كرنوبا ، أكسید الحدید الأصفر ، أكسید الحدید الأحمر.<br />وما ھي محتویات العبوة؟ ؟&trade; ما ھو شكل یوكیر<br />۱۰ ملجم أقراص مغلفة عبارة عن أقراص لونھا بیج ، على شكل مربع دائري، محفور على أحد &trade; یوكیر<br />.&quot; وعلى الجانب الآخر &quot; 98 &quot;JP&quot; جانبیھا<br />۱۰ ملجم أقراص مغلفة في عبوة تحتوي على ۳۰ قرص. &trade; یتوفر یوكی</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسویق و المصنع:<br />شركة مصنع جمجوم للأدویة، جدة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ۹٦٦ + فاكس: ٦۰۸۱۲۲۲ -۱۲- ھاتف: ٦۰۸۱۱۱۱<br />www.jamjoompharma.com : الموقع الإلكتروني<br />فضلا الإبلاغ عن الآثار الجانبیھ إلى:<br />المركز الوطني للتیقظ و السلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲<br />مركز إتصال ھیئة الغذاء و الدواء السعودیة: ۱۹۹۹۹<br />npc.drug@sfda.gov.sa : برید إلكتروني<br />https://ade.sfda.gov.sa : الموقع الالكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Yocair 10 mg Film coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 10 mg of Montelukast Sodium (Equivalent to 10 mg Montelukast) 10.40 mg.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated Tablets
Beige colored, rounded square shaped, film coated tablet, debossed with "JP" on one side and "98" on
the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short acting &beta;-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom Montelukast is indicated in asthma, Montelukast can also provide symptomatic relief of seasonal allergic rhinitis.<br />Montelukast is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended dose for adults and adolescents 15 years of age and older with asthma, or with<br />asthma and concomitant seasonal allergic rhinitis, is one 10 mg tablet daily to be taken in the evening. General recommendations<br />The therapeutic effect of Montelukast on parameters of asthma control occurs within one day. Montelukast may be taken with or without food. Patients should be advised to continue taking Montelukast even if their asthma is under control, as well as during periods of worsening asthma. Montelukast should not be used concomitantly with other products containing the same active ingredient, montelukast.<br />No dosage adjustment is necessary for the elderly, or for patients with renal insufficiency, or mild to<br />moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The<br />dosage is the same for both male and female patients. Therapy with Montelukast in relation to other treatments for asthma:<br />Montelukast can be added to a patient&#39;s existing treatment regimen.<br />Inhaled corticosteroids: Treatment with Montelukast can be used as add-on therapy in patients when<br />inhaled corticosteroids plus &ldquo;as needed&rdquo; short acting &beta;-agonists provide inadequate clinical control.<br />Montelukast should not be abruptly substituted for inhaled corticosteroids (see section 4.4).<br />Paediatric population<br />Do not give Montelukast 10 mg film-coated tablets to children less than 15 years of age. The safety<br />and efficacy of Montelukast 10 mg film-coated tablets in children less than 15 years has not been<br />established.<br />5 mg chewable tablets are available for paediatric patients 6 to 14 years of age.<br />4 mg chewable tablets are available for paediatric patients 2 to 5 years of age.<br />4 mg granules are available for paediatric patients 6 months to 5 years of age<br />Method of administration<br />Oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral Montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of short-acting &beta;-agonists than usual.<br />Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.<br />There are no data demonstrating that oral corticosteroids can be reduced when Montelukast is given concomitantly.<br />In rare cases, patients on therapy with anti-asthma agents including Montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.<br />Treatment with Montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or<br />glucose-galactose malabsorption should not take this medicine.</p><p>Neuropsychiatric events have been reported in adults, adolescents, and children taking Montelukast (see section 4.8). Patients and physicians should be alert for neuropsychiatric events. Patients and/or&nbsp;caregivers should be instructed to notify their physician if these changes occur. Prescribers should carefully evaluate the risks and benefits of continuing treatment with Montelukast if such events occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of Montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl oestradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.<br />The area under the plasma concentration curve (AUC) for Montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since Montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when Montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.<br />In vitro studies have shown that Montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving Montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolised by CYP 2C8) demonstrated that Montelukast does not inhibit CYP 2C8 in vivo. Therefore, Montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (eg., paclitaxel, rosiglitazone, and repaglinide).<br />In vitro studies have shown that Montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving Montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of Montelukast by 4.4-fold. No routine dosage adjustment of Montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.&nbsp;Based on in vitro data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of Montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of Montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.<br />Available data from published prospective and retrospective cohort studies with montelukast use in pregnant women evaluating major birth defects have not established a drug-associated risk. Available studies have methodologic limitations, including small sample size, in some cases retrospective data collection, and inconsistent comparator groups.<br />Montelukast may be used during pregnancy only if it is considered to be clearly essential. Breast-feeding<br />Studies in rats have shown that Montelukast is excreted in milk (see section 5.3). It is unknown whether Montelukast/metabolites are excreted in human milk.<br />Montelukast may be used in breast-feeding mothers only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has no or negligible influence on the ability to drive and use machines. However, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies as follows:<br />&bull; 10 mg film-coated tablets in approximately 4,000 adult and adolescent asthmatic patients 15 years of<br />age and older.<br />&bull; 10 mg film-coated tablets in approximately 400 adult and adolescent asthmatic patients with<br />seasonal allergic rhinitis 15 years of age and older.<br />&bull; 5 mg chewable tablets in approximately 1,750 paediatric asthmatic patients 6 to 14 years of age.<br />The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to<br />&lt;1/10) in asthmatic patients treated with montelukast and at a greater incidence than in patients<br />treated with placebo:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Body system Class</strong></p></td><td><p><strong>Adult and Adolescent Patients</strong></p><p><strong>15 years and older</strong></p><p><strong>(two 12-week studies; n=795)</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric Patients</strong></p><p><strong>6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201)</strong></p><p><strong>(two 56-week studies; n=615)</strong></p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p>headache</p></td><td><p>headache</p></td></tr><tr><td><p><strong>Gastrointestinal disorders</strong></p></td><td><p>abdominal pain</p></td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for</p><p>adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not</p><p>change.</p><p>&nbsp;</p><p><u>Tabulated list of Adverse Reactions</u></p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific</p><p>Adverse Reactions, in the table below. Frequency Categories were estimated based on relevant</p><p>clinical trials.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse experience term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>upper respiratory infection<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>increased bleeding tendency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorder</p></td><td style="vertical-align:top"><p>hypersensitivity reactions including anaphylaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>hepatic eosinophilic infiltration</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including irritability, restlessness, tremor<sup>&sect;</sup>)</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>disturbance in attention, memory impairment</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>hallucinations, disorientation, suicidal thinking and behaviour (suicidality)</p><p>Dysphemia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorder</p></td><td style="vertical-align:top"><p>dizziness, drowsiness paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>diarrhoea<sup>&Dagger;</sup>, nausea<sup>&Dagger;</sup>, vomiting<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>dry mouth, dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>elevated levels of serum transaminases (ALT, AST)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>rash<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>bruising, urticaria, pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>angiooedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>erythema nodosum</p><p>erythema multiforme</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>arthralgia, myalgia including muscle cramps</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>pyrexia<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>asthenia/fatigue, malaise, oedema,</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Frequency Category: Defined for each Adverse Experience Term by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><sup>&dagger;</sup>This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p><sup>&Dagger;</sup>This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.</p><p><sup>&sect;&nbsp;</sup>Frequency Category: Rare</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Toll free phone: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: <u>www.sfda.gov.sa/npc</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, Montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p>There have been reports of acute overdose in post-marketing experience and clinical studies with Montelukast. These include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports.</p><p>&nbsp;</p><p><u>Symptoms of overdose </u></p><p>The most frequently occurring adverse experiences were consistent with the safety profile of Montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p>&nbsp;</p><p><u>Management of overdose </u></p><p>No specific information is available on the treatment of overdose with Montelukast. It is not known whether Montelukast is dialysable by peritoneal- or hemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Leukotriene receptor antagonist</p><p>ATC-Code: R03D C03</p><p><u>Mechanism of action </u></p><p>The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from</p><p>various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to</p><p>cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found in the human</p><p>airway (including airway smooth muscle cells and airway macrophages) and on other proinflammatory</p><p>cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis. Intranasal challenge with CysLTs has been shown to increase nasal airway resistance and symptoms of nasal obstruction.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects </u></p><p>Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. In clinical studies, Montelukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused by Montelukast. Treatment with Montelukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with Montelukast significantly decreased eosinophils in the airways (as measured in sputum). In adult and paediatric patients 2 to 14 years of age, Montelukast, compared with placebo, decreased peripheral blood eosinophils while improving clinical asthma control.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Clinical efficacy and safety: </u></p><p>In studies in adults, Montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV1 (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and nighttime asthma symptoms scores was significantly better than placebo.</p><p>&nbsp;</p><p>Studies in adults demonstrated the ability of Montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus Montelukast vs beclomethasone, respectively for FEV1: 5.43% vs 1.04%; &beta;-agonist use: -8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device), Montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for Montelukast vs beclomethasone, respectively for FEV1: 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high percentage of patients treated with Montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV1 of approximately 11% or more over baseline while approximately 42% of patients treated with Montelukast achieved the same response).</p><p>&nbsp;</p><p>A clinical study was conducted to evaluate montelukast for the symptomatic treatment of seasonal allergic rhinitis in adult and adolescent asthmatic patients 15 years of age and older with concomitant seasonal allergic rhinitis. In this study, montelukast 10 mg tablets administered once daily demonstrated a statistically significant improvement in the Daily Rhinitis Symptoms score, compared with placebo. The Daily Rhinitis Symptoms score is the average of the Daytime Nasal Symptoms score (mean of nasal congestion, rhinorrhea, sneezing, nasal itching) and the Nighttime Symptoms score (mean of nasal congestion upon awakening, difficulty going to sleep, and nighttime awakenings scores). Global evaluations of allergic rhinitis by patients and physicians were significantly improved, compared with placebo. The evaluation of asthma efficacy was not a primary objective in this study.</p><p>&nbsp;</p><p>In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV1 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &quot;as-needed&quot; &beta;-agonist use (-11.7% vs +8.2% change from baseline).</p><p>&nbsp;</p><p>Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV1 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV1 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in paediatric patients (maximal fall in FEV1 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV1 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p>&nbsp;</p><p>In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV1 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption </u></p><p>Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p>For the 5 mg chewable tablet, the Cmax is achieved in 2 hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of Montelukast averages 8-11 litres. Studies in rats with radiolabelled Montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p>&nbsp;</p><p><u>Biotransformation </u></p><p>Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of Montelukast are undetectable at steady state in adults and children.</p><p>Cytochrome P450 2C8 is the major enzyme in the metabolism of Montelukast. Additionally CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of Montelukast in healthy subjects that received 10 mg Montelukast daily. Based on in vitro results in human liver microsomes, therapeutic plasma concentrations of Montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of Montelukast is minimal.</p><p>&nbsp;</p><p><u>Elimination </u></p><p>The plasma clearance of Montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled Montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of Montelukast oral bioavailability, this indicates that Montelukast and its metabolites are excreted almost exclusively via the bile.</p><p>&nbsp;</p><p><u>Characteristics in Patients </u></p><p>No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because Montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of Montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p>With high doses of Montelukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastro-intestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, Montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p>No deaths occurred following a single oral administration of Montelukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats, respectively), the maximum dose tested. This does is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p>Montelukast was neither mutagenic in in vitro and in vivo tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p> Mannitol (Pearlitol 25 C)</p><p> Microcrystalline Cellulose PH101</p><p> Croscarmellose Sodium</p><p> Hydroxy Propyl Cellulose</p><p> Iron Oxide Red</p><p> Aspartame</p><p> Art Cherry Flavor</p><p> Magnesium Stearate</p><p> Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                     24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-Alu blister pack</p><p>Pack sizes: 3 X 10&rsquo;s Blister Pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company 
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442,
Kingdom of Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>